LEIF ELLISEN

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Regulation of gene expression by WT1 in development and tumorigenesis
    Leif W Ellisen
    Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Int J Hematol 76:110-6. 2002
  2. pmc Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora Dias-Santagata
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    EMBO Mol Med 2:146-58. 2010
  3. ncbi request reprint Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
  4. pmc BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma
    Nageatte Ibrahim
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Res 70:7155-65. 2010
  5. ncbi request reprint p63 and p73: life and death in squamous cell carcinoma
    James W Rocco
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 5:936-40. 2006
  6. ncbi request reprint p63 regulates an adhesion programme and cell survival in epithelial cells
    Danielle K Carroll
    Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA
    Nat Cell Biol 8:551-61. 2006
  7. pmc Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma
    William A Michaud
    Massachusetts General Hospital MGH Cancer Center, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 15:1645-54. 2009
  8. ncbi request reprint p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
    James W Rocco
    Massachusetts General Hospital Center for Cancer Research and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Cell 9:45-56. 2006
  9. pmc Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling
    Maurice Phillip DeYoung
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    Genes Dev 22:239-51. 2008
  10. pmc Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells
    Na Li
    Department of Pharmacology and Toxicology, Dartmouth Medical School, 7650 Remsen, Hanover, New Hampshire 03755, USA
    Stem Cells 26:1253-64. 2008

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Regulation of gene expression by WT1 in development and tumorigenesis
    Leif W Ellisen
    Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Int J Hematol 76:110-6. 2002
    ..Recently, a hematopoietic model system has been used to study functional properties of WT1 in vitro. WT1 expression in primary hematopoietic cells leads to stage-specific effects that may be relevant to WT1-mediated tumor suppression...
  2. pmc Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora Dias-Santagata
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    EMBO Mol Med 2:146-58. 2010
    ..This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management...
  3. ncbi request reprint Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
    ..We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer...
  4. pmc BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma
    Nageatte Ibrahim
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Res 70:7155-65. 2010
    ..TAp73 might represent a response predictor and potential therapeutic target for enhancing chemosensitivity in this disease...
  5. ncbi request reprint p63 and p73: life and death in squamous cell carcinoma
    James W Rocco
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 5:936-40. 2006
    ..Specific chemotherapeutic agents and future targeted approaches may be able to exploit this pathway to therapeutic advantage...
  6. ncbi request reprint p63 regulates an adhesion programme and cell survival in epithelial cells
    Danielle K Carroll
    Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA
    Nat Cell Biol 8:551-61. 2006
    ..Our results implicate p63 as a key regulator of cellular adhesion and survival in basal cells of the mammary gland and other stratified epithelial tissues...
  7. pmc Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma
    William A Michaud
    Massachusetts General Hospital MGH Cancer Center, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 15:1645-54. 2009
    ....
  8. ncbi request reprint p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
    James W Rocco
    Massachusetts General Hospital Center for Cancer Research and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Cell 9:45-56. 2006
    ..Together, these data define a pathway whereby deltaNp63alpha promotes survival in squamous epithelial malignancy by repressing a p73-dependent proapoptotic transcriptional program...
  9. pmc Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling
    Maurice Phillip DeYoung
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    Genes Dev 22:239-51. 2008
    ..Together, these findings define a molecular mechanism of signal integration by TSC1/2 that provides insight into the ability of REDD1 to function in a hypoxia-dependent tumor suppressor pathway...
  10. pmc Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells
    Na Li
    Department of Pharmacology and Toxicology, Dartmouth Medical School, 7650 Remsen, Hanover, New Hampshire 03755, USA
    Stem Cells 26:1253-64. 2008
    ..These studies support a model in which hedgehog activates elaboration and differentiation of mammary progenitors via differential TP63 promoter selection and forfeiture of self-renewing capacity...
  11. ncbi request reprint REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species
    Leif W Ellisen
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA
    Mol Cell 10:995-1005. 2002
    ..Thus, REDD1 encodes a shared transcriptional target that implicates ROS in the p53-dependent DNA damage response and in p63-mediated regulation of epithelial differentiation...
  12. pmc The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
    Chee Onn Leong
    Massachusetts General Hospital Cancer Center and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Clin Invest 117:1370-80. 2007
    ....

Research Grants12

  1. Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
    Leif W Ellisen; Fiscal Year: 2010
    ....
  2. TELOMERASE FUNCTIONS IN DIFFERENTIATION & TRANSFORMATION
    LEIF ELLISEN; Fiscal Year: 2003
    ..This work should further our understanding of the how events at the telomere regulate normal and malignant cell growth. ..
  3. P63 mediators as therapeutic targets in HNSCC
    LEIF ELLISEN; Fiscal Year: 2009
    ..In addition to improving our knowledge of the basic biology of HNSCC, these studies will advance the goal of uncovering novel and viable therapeutic targets to improve treatment outcomes in this disease. ..
  4. Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
    LEIF ELLISEN; Fiscal Year: 2007
    ....
  5. P63 mediators as therapeutic targets in HNSCC
    LEIF ELLISEN; Fiscal Year: 2007
    ..Together these studies will define the relevance of the p63 pathway in tumorigenesis, and will identify potential new therapeutic targets that mediate the critical survival effect of p63 in HNSCC. ..
  6. P63 mediators as therapeutic targets in HNSCC
    Leif W Ellisen; Fiscal Year: 2010
    ..In addition to improving our knowledge of the basic biology of HNSCC, these studies will advance the goal of uncovering novel and viable therapeutic targets to improve treatment outcomes in this disease. ..